Contract laboratories specializing in biologics research now have access to the Cydem VT Automated Clone Screening System, the latest innovation from Beckman Coulter Life Sciences. This state-of-the-art platform offers a high-throughput, automated solution for clone screening, reducing time-to-market for biologic drugs and monoclonal antibody (mAb) therapeutics.
The Cydem VT System integrates multiple trusted technologies into one seamless workflow, delivering early, reliable answers on cell growth and productivity. Its parallel cultivation of up to 96 bioreactors, combined with automated pH, dissolved oxygen (DO), and titer monitoring, ensures optimal clone selection and cultivation conditions.
Why Contract Testing Labs Choose the Cydem VT System:
- Reduced Time-to-Market: Automates up to 90% of manual screening steps.
- Walk-Away Capability: Provides at least three days of uninterrupted experimentation.
- Superior Screening: Detects viable clones faster with on-deck cell health and productivity analysis.
- Reproducible Results: Mimics biomanufacturing conditions for accurate scale-up.
- Maximized Efficiency: Combines multiple functions into one all-in-one platform.
With the Cydem VT System, contract testing labs can deliver faster, more reliable results to their clients, driving innovation in biologic drug development.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: “Beckman Coulter Life Sciences Accelerates Drug Discovery with Launch of Cydem VT Automated Clone Screening System.“
